4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Hidradenitis Suppurativa by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 308 ongoing clinical trials involving Hidradenitis Suppurativa
Of the 308 trials,149 trials are in Phase III
Furthermore, 73 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Hidradenitis Suppurativa by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Hidradenitis Suppurativa, a Dermatology condition. The largest number of ongoing clinical trials for Hidradenitis Suppurativa is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Hidradenitis Suppurativa-related drug trials.

Novartis AG and UCB SA: The leading ongoing Hidradenitis Suppurativa related clinical trial sponsors

Novartis AG and UCB SA are the top sponsors for Hidradenitis Suppurativa-related ongoing clinical trials.

Pfizer Inc, Staidson (Beijing) Biopharmaceuticals Co Ltd, Erasmus MC, and AbbVie Inc are among other notable clinical trial sponsors involved in Hidradenitis Suppurativa. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Hidradenitis Suppurativa

Adalimumab (Humira), Adalimumab-atto (Amjevita/ Solymbic), and Adalimumab (Imraldi/Hadlima/Adalloce) are among the key marketed drugs involving Hidradenitis Suppurativa.

Adalimumab (Humira) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). It functions via Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF) Inhibitor mechanism of action. Adalimumab is formulated as injection for subcutaneous route of administration. Humira is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis, for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Adalimumab was first approved in 2002 and is marketed globally in the US, Japan, the UK, China, Germany and France by several prominent pharma giants including AbbVie Inc.

Adalimumab-atto (Amjevita/ Solymbic) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor. It functions via Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF) Inhibitor mechanism of action. Adalimumab-atto is formulated as solution for subcutaneous route of administration. Adalimumab-atto was first approved in 2016 and is marketed globally including the US, the UK, Australia, France and Germany by Amgen Inc and its subsidiaries.